The Utility of PET/CT in Erlotinib treatment for Non-Small Cell cancer
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000002044
- Lead Sponsor
- Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)History of radiation therapy for primary site 2)Severe infection 3)Bowel obstruction 4)Interstitioal pneumonia or lung fibrosis 5)History of any thoracic radiation therapy 6)Active concomitant malignancy 7)Sever heart disease 8)No regulatory condition because of psychological disease 9)Pregnant women or somen willing child-bearing 10)inadequate condition siagnosed by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relationship between uptake of FDG 2 days after the erlotinib administration and tumor size on CT
- Secondary Outcome Measures
Name Time Method OS, PFS